XML 33 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
(LOSS) EARNINGS PER SHARE
 9 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
(LOSS) EARNINGS PER SHARE
(LOSS) EARNINGS PER SHARE
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc. for the three-month and nine-month periods ended September 30, 2016 and 2015 were calculated as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2016
 
2015
 
2016
 
2015
(restated)
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.
$
(1,218.4
)
 
$
49.5

 
$
(1,894.4
)
 
$
94.2

 
 
 
 
 
 
 
 
Basic weighted-average number of common shares outstanding
349.5

 
344.9

 
346.5

 
340.8

Diluted effect of stock options, RSUs and other(a)
—

 
6.1

 
—

 
6.4

Diluted weighted-average number of common shares outstanding
349.5

 
351.0

 
346.5

 
347.2

 
 
 
 
 
 
 
 
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:
 
 
 
 
 
 
 
Basic
$
(3.49
)
 
$
0.14

 
$
(5.47
)
 
$
0.28

Diluted
$
(3.49
)
 
$
0.14

 
$
(5.47
)
 
$
0.27


____________________________________
(a)
In the three-month and nine-month periods ended September 30, 2016, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
 
 
Three Months Ended
September 30,
 
Nine Months
Ended
September 30,
 
 
2016
 
2016(1)
Basic weighted-average number of common shares outstanding
 
349.5

 
346.5

Diluted effect of stock options, RSUs and other
 
0.8

 
3.4

Diluted weighted-average number of common shares outstanding
 
350.3

 
349.9

____________________________________
(1)
The calculation of diluted weighted-average number of common shares outstanding for the nine-month period ended September 30, 2016 reflects the adjustment to the calculation for six-month period ended June 30, 2016 as a result of the adoption of a new accounting standard, effective as of January 1, 2016. Refer to Note 3 for further details.
In the three-month and nine-month periods ended September 30, 2016, stock options, time-based RSUs and performance-based RSUs to purchase approximately 8,300,000 common shares of the Company in both of the corresponding periods were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method, compared with 442,000 and 540,000 common shares in both of the corresponding periods of 2015.